ACDF Brief comments: The evolving role of SGLT2 inhibitors

Expert faculty provide brief commentaries on content related to the Asian Cardio Diabetes Forum 2019. Prof. Mark Cooper comments on the question how he thinks the role of SGLT-2 inhibitors would evolve in addressing kidney disease?

Faculty

Mark Cooper, MD, Head of Diabetes Department in the Central Clinical School, Monash University, Melbourne, Australia

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

The Asian Cardio Diabetes Forum was funded by Boehringer Ingelheim Singapore